Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Endometrial Neoplasms 1Carcinoma, Ductal, Breast 1

Interventions

pembrolizumab 49Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 16Cyclophosphamide 14Cisplatin 14Paclitaxel 13Carboplatin 13Bevacizumab 13Leucovorin 11Irinotecan 11Fluorouracil 11Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Capecitabine 10trastuzumab deruxtecan 9fludarabine 9cemiplimab 8Doxorubicin 8Cetuximab 8abemaciclib 7Trastuzumab 7Pemetrexed 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × TP protocol × Clear all
NCT06532539 2026-04-24

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
30 enrolled
Gynecologic

Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡